Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-α antagonist therapy: Safe re-initiation of TNF-α blockers after appropriate anti-tuberculous treatment

Clinical Microbiology and Infection

Volumn 14, Issue 2, 2008, Pages 183-186

  Denis, B ^a   Lefort, A ^b   Flipo, R M ^c   Tubach, F ^b   Lemann, M ^b   Ravaud, P ^b   Salmon, D ^b   Mariette, X ^d   Lortholary, Oliver ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antagonist treatment; Mortality rate; Mycobacterium tuberculosis; Tuberculosis; Tumour necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETHAMBUTOL; HYDROXYCHLOROQUINE; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; OFLOXACIN; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACID FAST BACTERIUM; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL VIRULENCE; BREAST CARCINOMA; CHRONIC HEPATITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COUGHING; DRUG REEXPOSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MICROSCOPY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THYROID CARCINOMA; TREATMENT RESPONSE; TUBERCULIN TEST; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 38049019107     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01891.x     Document Type: Article

References (9)

1. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-740.
2. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143: 2894-2899.
3. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M.avium: Killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991; 49: 380-387.
4. Keane J, Gershon S, Wise RP etal. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
5. Askling J, Fored CM, Brandt L etal. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-1992.
6. Gardam MA, Keystone EC, Menzies R etal. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155.
7. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379.
8. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005; 44: 157-163.
9. Anonymous. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-805.